[go: up one dir, main page]

CY1112269T1 - Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος - Google Patents

Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος

Info

Publication number
CY1112269T1
CY1112269T1 CY20121100109T CY121100109T CY1112269T1 CY 1112269 T1 CY1112269 T1 CY 1112269T1 CY 20121100109 T CY20121100109 T CY 20121100109T CY 121100109 T CY121100109 T CY 121100109T CY 1112269 T1 CY1112269 T1 CY 1112269T1
Authority
CY
Cyprus
Prior art keywords
reduction
treatment
compositions
improvement
red
Prior art date
Application number
CY20121100109T
Other languages
English (en)
Inventor
Raili Kerppola
Gary Phillips
Zhenze Hu
Keith Wayne Ward
Original Assignee
Bausch & Lomb Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb Incorporated filed Critical Bausch & Lomb Incorporated
Publication of CY1112269T1 publication Critical patent/CY1112269T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Μία σύνθεση για την αγωγή, μείωση, βελτίωση, ή ανακούφιση μιας κατάστασης ή διαταραχής του πίσω-μέρους-του-οφθαλμού που έχει μια αιτιολογία στην φλεγμονή περιλαμβάνει έναν διαχωρισμένο αγωνιστή του υποδοχέα των γλυκοκορτικοειδών ("DIGRA"). Οι συνθέσεις μπορούν επίσης να συμπεριλάβουν και άλλους αντι-φλεγμονώδεις παράγοντες, αντι-αγγειογόνους παράγοντες ή συνδυασμούς εξ αυτών. Η σύνθεση μπορεί να τυποποιηθεί παρασκευαστικώς για τοπική εφαρμογή, ένεση, ή εμφύτευση. Η σύνθεση μπορεί να χορηγηθεί μόνη της ή σε συνδυασμό με μία άλλη διαδικασία που επιλέγεται για να επαυξήσει την έκβαση της αγωγής.
CY20121100109T 2006-08-07 2012-02-01 Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος CY1112269T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83607806P 2006-08-07 2006-08-07
EP07813637A EP2051710B1 (en) 2006-08-07 2007-08-01 Compositions and methods for treating, reducing, ameliorating, or alleviating posterior-segment ophthalmic diseases

Publications (1)

Publication Number Publication Date
CY1112269T1 true CY1112269T1 (el) 2015-12-09

Family

ID=38823645

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100109T CY1112269T1 (el) 2006-08-07 2012-02-01 Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος

Country Status (18)

Country Link
US (1) US20080031884A1 (el)
EP (1) EP2051710B1 (el)
JP (1) JP2010500364A (el)
KR (1) KR20090051076A (el)
CN (1) CN101522187A (el)
AT (1) ATE531366T1 (el)
AU (1) AU2007284176B2 (el)
BR (1) BRPI0714817A2 (el)
CA (1) CA2660167C (el)
CY (1) CY1112269T1 (el)
DK (1) DK2051710T3 (el)
ES (1) ES2373999T3 (el)
MX (1) MX2009001333A (el)
PL (1) PL2051710T3 (el)
PT (1) PT2051710E (el)
SI (1) SI2051710T1 (el)
TW (1) TWI378928B (el)
WO (1) WO2008021729A2 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2056799T1 (sl) 2006-08-31 2013-11-29 Bausch & Lomb Incorporated Sestavki in postopki za zdravljenje ali preprečevanje glavkoma ali njegovega napredovanja
US20090042936A1 (en) * 2007-08-10 2009-02-12 Ward Keith W Compositions and Methods for Treating or Controlling Anterior-Segment Inflammation
SG185955A1 (en) * 2007-11-05 2012-12-28 Bausch & Lomb Water-immiscible materials as vehicles for drug delivery
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
US20100008993A1 (en) * 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
US20110077270A1 (en) * 2009-04-21 2011-03-31 Pfeffer Bruce A Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
RU2559585C2 (ru) * 2013-12-26 2015-08-10 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ диагностики раннего воздействия вредных производственных факторов на организм работников, занятых в производстве синтетических смол не более 5 лет
ES2980934T3 (es) 2019-01-22 2024-10-03 Akribes Biomedical Gmbh Modificadores selectivos del receptor de glucocorticoides para tratar la cicatrización alterada de heridas en la piel
EP4103197A4 (en) * 2020-02-13 2024-02-14 Spiral Therapeutics Inc. TREATMENT OF OTIC DISEASES AND CONDITIONS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4580559A (en) * 1984-07-24 1986-04-08 Esperance Francis A L Indirect ophthalmoscopic photocoagulation delivery system for retinal surgery
WO2000000194A1 (en) * 1998-06-27 2000-01-06 Photogenesis, Inc. Ophthalmic uses of ppargamma agonists and ppargamma antagonists
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
DK1521733T3 (da) * 2002-07-08 2014-10-13 Pfizer Prod Inc Modulatorer af glucocorticoid receptoren
US7235662B2 (en) * 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer

Also Published As

Publication number Publication date
CA2660167C (en) 2012-04-10
CN101522187A (zh) 2009-09-02
WO2008021729A3 (en) 2008-10-09
EP2051710A2 (en) 2009-04-29
MX2009001333A (es) 2009-02-13
CA2660167A1 (en) 2008-02-21
US20080031884A1 (en) 2008-02-07
PT2051710E (pt) 2012-02-08
WO2008021729A2 (en) 2008-02-21
SI2051710T1 (sl) 2012-02-29
BRPI0714817A2 (pt) 2013-05-21
TWI378928B (en) 2012-12-11
ES2373999T3 (es) 2012-02-10
TW200815416A (en) 2008-04-01
ATE531366T1 (de) 2011-11-15
EP2051710B1 (en) 2011-11-02
AU2007284176A1 (en) 2008-02-21
HK1127556A1 (en) 2009-10-02
JP2010500364A (ja) 2010-01-07
AU2007284176B2 (en) 2013-03-28
PL2051710T3 (pl) 2012-03-30
DK2051710T3 (da) 2012-02-20
KR20090051076A (ko) 2009-05-20

Similar Documents

Publication Publication Date Title
CY1112269T1 (el) Συνθεσεις και μεθοδοι για την αγωγη, μειωση, βελτιωση, ή ανακουφιση των οφθαλμικων παθησεων οπισθιου- τμηματος
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
NO20065368L (no) Terapeutiske blandinger inneholdende minst et pyrrolobenzodiazepinderivat og fludarabin
AR066916A1 (es) Anticuerpos conra c3b y metodos para la prevenc ion y el tratamiento de trastornos asociados con el complemento. composicion farmaceutica.
BRPI0414082A (pt) formas de dosagem de liberação sustentada de ziprasidona
EP2513343A4 (en) METHOD AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION
CL2011001131A1 (es) Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp)
CY1110199T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
BRPI0414277A (pt) métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
CL2016003014A1 (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) (divisional sol. n°230-11).
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
TR201900542T4 (tr) Ağrı ve/veya enflamasyon tedavisi için bileşimler.
BRPI0714399B8 (pt) composição farmacêutica líquida oral
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
CY1108430T1 (el) Χρηση ανταγωνιστων διαυλου νευρωνικου νατριου μαζι με αμιτραζ για τον ελεγχο εκτοπαρασιτων σε ομοιοθερμικα ζωα
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
AR072805A1 (es) Composiciones intranasales formas galenicas y metodos de tratamiento.
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
CY1123398T1 (el) Συνθεση συνδυασμου
ECSP034624A (es) Combinacion de agonista de gava e inhibidores de sorbitol-deshidrogenasa
CL2010001406A1 (es) Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion.
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
MX2007009032A (es) Formulacion para inyeccion de butanos catecolicos incluyendo compuestos ndga en animales.